PARIN5, a Novel Thrombin Receptor Antagonist Modulates a Streptozotocin Mice Model for Diabetic Encephalopathy
International Journal of Molecular Sciences · 19.01.2023 · 24 (3) · 2021
DOI: 10.3390/ijms24032021 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.01.2023. Verfasst von Valery Golderman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Thrombin, Receptor, PAR-1, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diabetic encephalopathy (DE) is an inflammation-associated diabetes mellitus (DM) complication. Inflammation and coagulation are linked and are both potentially modulated by inhibiting the thrombin cellular protease-activated receptor 1 (PAR1). Our aim was to study whether coagulation pathway modulation affects DE. Diabetic C57BL/6 mice were treated with PARIN5, a novel PAR1 modulator. Behavioral changes in the open field and novel object recognition tests, serum neurofilament (NfL) levels and thrombin activity in central and peripheral nervous system tissue (CNS and PNS, respectively), brain mRNA expression of tumor necrosis factor α (TNF-α), Factor X (FX), prothrombin, and PAR1 were assessed. Subtle behavioral changes were detected in diabetic mice. These were accompanied by an increase in serum NfL, an increase in central and peripheral neural tissue thrombin activity, and TNF-α, FX, and prothrombin brain intrinsic mRNA expression. Systemic treatment with PARIN5 prevented the appearance of behavioral changes, normalized serum NfL and prevented the increase in peripheral but not central thrombin activity. PARIN5 treatment prevented the elevation of both TNF-α and FX but significantly elevated prothrombin expression. PARIN5 treatment prevents behavioral and neural damage in the DE model, suggesting it for future clinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.
- Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
- Goldschleger Eye Institute, The Sheba Medical Center, Ramat Gan 52626202, Israel.
- Talpiot Medical Leadership Program, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.
- Robert and Martha Harden Chair in Mental and Neurological Diseases, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
ORCID-Profile: Valery Golderman, Zehavit Goldberg, Shany Guly Gofrit, Amir Dori, Joab Chapman, Ifat Sher, Efrat Shavit-Stein
Zitieren
APA
Golderman, V., Goldberg, Z., Gofrit, S. G., Dori, A., Maggio, N., Chapman, J., Sher, I., Rotenstreich, Y., & Shavit-Stein, E. (2023). PARIN5, a Novel Thrombin Receptor Antagonist Modulates a Streptozotocin Mice Model for Diabetic Encephalopathy. International Journal of Molecular Sciences, 24(3), 2021. https://doi.org/10.3390/ijms24032021
Vancouver
Golderman V, Goldberg Z, Gofrit SG, Dori A, Maggio N, Chapman J, et al. PARIN5, a Novel Thrombin Receptor Antagonist Modulates a Streptozotocin Mice Model for Diabetic Encephalopathy. International Journal of Molecular Sciences. 2023;24(3):2021. doi:10.3390/ijms24032021
BibTeX
@article{Golderman2023,
author = {Golderman, Valery and Goldberg, Zehavit and Gofrit, Shany Guly and Dori, Amir and Maggio, Nicola and Chapman, Joab and Sher, Ifat and Rotenstreich, Ygal and Shavit-Stein, Efrat},
title = {PARIN5, a Novel Thrombin Receptor Antagonist Modulates a Streptozotocin Mice Model for Diabetic Encephalopathy},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {3},
pages = {2021},
doi = {10.3390/ijms24032021}
}
EUVIMED